Biotechnology

RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB

* Radiopharm will shortly initiate a PD-L1 Phase 1 therapeutic study in Australia in patients with NSCLC * Radiopharm acquired from NanoMab, Ltd. worldwide rights to PD-L1 technology for therapeutic use, as well as to imaging rights inChina MELBOURNE, Australia, Aug. 3, 2022 /PRNewswire/ -- R...

2022-08-04 10:15 1564

ST Pharm Presents Phase 1 Clinical Trial Results of HIV Treatment Candidate at AIDS 2022

-   STP0404 is the only clinical safety proven HIV treatment candidate with a novel mechanism that can block HIV re-activation. -   STP0404 is expected to enter Phase 2a clinical trial in the US in 4Q 2022. SEOUL, South Korea, Aug. 3, 2022 /PRNewswire/ -- ST Pharm Co., Ltd. (237690:KOSDAQ) annou...

2022-08-03 20:00 1898

Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

SUZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company completed the enrollment of 121 patients for its pha...

2022-08-03 19:38 1506

Sanyou Biopharmaceuticals Closed the Series B+ Financing Round of Tens of Millions of RMB Led by Huatai Zijin

SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. announced that it has closed the Series B+ financing round of tens of millions of RMB. In this round of financing led by Zijin Hongyun Fund and Huatai Guoxin Fund under Huatai Zijin, Sanyou also received follow-on investme...

2022-08-03 08:00 1724

GenKOre develops hypercompact base editing system

DAEJEON, South Korea , Aug. 2, 2022 /PRNewswire/ -- GenKOre (homepage: www.genkore.com ), a biotech start-up in Korea, had a study on the development of hypercompact adenine base editors (ABEs) published on Nature Chemical Biology onAugust 2, 2022.

2022-08-02 22:44 2082

Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Aug. 2, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today a...

2022-08-02 21:00 1976

CARsgen Appoints Dr. Hua Jiang as Executive Director

SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatDr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Direct...

2022-08-02 20:50 2127

"OpenDEL®3.0 - DRUG DISCOVERY PARTNER" webinar offered by HitGen and Endpoints News coming up on Thursday 4th August

CHENGDU, China, Aug. 1, 2022 /PRNewswire/ -- "OpenDEL®3.0 – DRUG DISCOVERY PARTNER" webinar will be jointly held by HitGen Inc. and Endpoints News on Thursday 4th August, to present you with a high-quality DEL product with all DEL information sharing and technical support. Dr. Guansai Liu, Execut...

2022-08-01 22:00 1945

Yunji's Technology-empowered Private Label SUYE Celebrates Its 12th Anniversary

HANGZHOU, China, Aug. 1, 2022 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced the celebration of its private-label skin care brand SUYE's 12th anniversary. SUYE generated over21 million RMB sales of its hig...

2022-08-01 21:00 2688

GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine

* GreenLight's messenger RNA production process is transferable to large-scale equipment and CMO facilities * Technology transfer and scale-up from lab bench to Samsung's commercial facility was completed in seven months * GreenLight's mRNA synthesis reaction had a titer of 12g/L at a commer...

2022-08-01 21:00 2245

Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer

Dr. Li brings deep oncology clinical development, medical affairs and U.S. regulatory experience SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 1, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical compa...

2022-08-01 20:00 1903

Eccogene Announces US IND Approval for THRβ agonist ECC4703

SHANGHAI, Aug. 1, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S. This study will evaluate the safety, tolerabilit...

2022-08-01 15:00 1511

HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update

* Financial performance for Q2 2022 records revenues of KRW 26.2 billion, a 12% growth from the same period last year, driven by strong sales performance from the pharmaceutical division   * Operating income turned to profit compared to the last quarter, while investment to R&D continued in t...

2022-07-29 20:00 2936

ZAODX World Conference on Early Detection of Cancer was successfully held in Guangzhou, China

GUANGZHOU, China, July 29, 2022 /PRNewswire/ -- The inaugural ZAODX World Conference on Early Detection of Cancer ("the Conference") was successfully held at the Chimelong International Conference Center inGuangzhou from July 15-17, 2022. In attendance were founders and representatives from over ...

2022-07-29 15:35 1506

Taiwan Startup PrecisemAb Continues Progress Towards Vision of Safest Antibody Treatment With No Side Effects

The Universal Antibody Lock technology will give patients more of a choice TAIPEI, July 29, 2022 /PRNewswire/ -- PrecisemAb Biotech , a biotechnology research company based in Kaohsiung,Taiwan, continues to stay true to its vision of enhancing antibody drugs b...

2022-07-29 12:09 1484

The Taiwanese Startup Mindtronic AI Opens the Way to the Future of Mobility With Meta-Service Ecosystem

The Taiwanese start-up marks its fifth CES Innovation Award win since 2018 with its auto technology. LAS VEGAS, July 29, 2022 /PRNewswire/ -- Mindtronic AI ( https://www.mindtronicai.com/ ), a Taiwan-based startup, unveils the world's first Meta-Service, a biometric...

2022-07-29 12:01 1647

Ubiquitome's Liberty16 Pro ready to carve up next COVID wave

Faster mobile PCR test device helping business continuity CHICAGO, July 28, 2022 /PRNewswire/ -- Ubiquitome , which won through the United States' NIH RADx shark tank

2022-07-28 20:39 1855

Plant-Oil-Based Skincare Technology Business Available for License or Purchase

A NEW AND UNIQUE ANHYDROUS SKINCARE TECHNOLOGY OF PROVEN VERY HIGH EFFICACY  AUCKLAND, New Zealand, July 27, 2022 /PRNewswire/ -- Invented and developed by the CEO ofFutecNZ Limited in New Zealand, (trading under the ONE24 brand) trialled and tested by accredited scientific laboratories, a vast t...

2022-07-28 05:22 1485

Origin Agritech Receives a $35 Million Order from Muyuan Foods

Companies Plan to Expand Partnership Significantly Beyond This Initial Order BEIJING, July 27, 2022 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, announced today that the company has received an order for its hybrid corn worthR...

2022-07-27 23:06 2380

Portfolio Highlights: Clinical and Financing Updates of AIxplorerBIO, Genhouse, VivaVision, Domain, Amberstone, Anji and QurAlis

SHANGHAI, China, July 27, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 month, its portfolio companies have had great progress. AIxplorerBIO...

2022-07-27 21:30 2243
1 ... 71727374757677 ... 127